好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Identifying an Optimal Cut-off Value and if Sex Differences Exist in Nigrostriatal Dopamine Transporter Binding of 123I-FP-CIT SPECT in Autopsy Confirmed Lewy Body Disease and/or Alzheimer’s Disease
Aging, Dementia, and Behavioral Neurology
P10 - Poster Session 10 (5:00 PM-6:00 PM)
3-002

To assess 123I-FP-CIT SPECT (DaT-SPECT) in autopsy confirmed Lewy body disease (LBD) and/or Alzheimer’s disease (AD) patients, and to identify if sex differences exist.
Identifying optimal cut-off value for DaT-SPECT in detecting LBD is essential in LBD clinical trials and research. Effects of sex in nigrostriatal dopamine transporter (DaT) binding of the DaT-SPECT in autopsy confirmed LBD is not well known.
Autopsy confirmed neocortical or limbic LBD and/or AD patients who underwent DaT-SPECT were included. Nigrostriatal DaT binding and z-scores were assessed using DaTQUANT2.0 software (GE Healthcare).
Thirty-three patients had LBD pathology [19 without AD (L+/A-) and 14 with AD (L+/A+); 30 neocortical and 3 limbic LBD; 26 male and 7 female] and 12 had AD pathology without LBD (L-/A+). A cut-off value of -0.98 for the DaTQUANT putamen z-score yielded 94% sensitivity and 100% specificity in detecting LBD. Age at death, age at DaT-SPECT, MMSE, UPDRS part III, and DaTQUANT z-score of putamen (-3.55±0.97 vs -2.94±1.71) or caudate (-2.77±1.18 vs -2.46±1.48) did not differ between the L+/A- and L+/A+. Males were more frequent in L+/A- (95%) than in L+/A (57%). Age at death, age at DaT-SPECT, interval between DaT-SPECT and death, and MMSE did not differ between the L+ males and females. The L+ females had more frequent AD co-pathology (86% vs 31%), more AD dementia clinical diagnosis (29% vs 0%), lower UPDRS part-III (11.4±12.3 vs 23.2±13.0), and higher DaTQUANT putamen (-2.17±1.98 vs -3.60±0.97) and caudate (-1.65±1.64 vs -2.90±1.08) z-scores. All L+ females had neocortical LBD, and the two L+ females with AD clinical diagnosis had normal DaT-SPECT and L+/A+ pathology. 
DaTQUANT using cut-off putamen z-score value of -1 showed excellent discriminatory power in detecting LBD pathology. Though limited by relatively few females, there were potential sex differences observed in DaT-SPECT as well as in clinical and pathological findings.
Authors/Disclosures
Toji Miyagawa, MD, PhD (Mayo Clinic)
PRESENTER 		Dr. Miyagawa has nothing to disclose.
Scott Przybelski Scott Przybelski has nothing to disclose.
Cynthia Vernon (Mayo Clinic) Cynthia Vernon has nothing to disclose.
Paul Min (Mayo Clinic) No disclosure on file
Leah K. Forsberg, PhD (Mayo Clinic) Ms. Forsberg has nothing to disclose.
Julie A. Fields, PhD (Mayo Clinic) The institution of Dr. Fields has received research support from National Institutes of Health. The institution of Dr. Fields has received research support from Patient-Centered Outcomes Research Institute.
Stuart J. McCarter, MD (Mayo Clinic) The institution of Dr. McCarter has received research support from NIH. The institution of Dr. McCarter has received research support from American Academy of Sleep Medicine Foundation.
Tanis J. Ferman, PhD (Mayo Clinic Jacksonville) Ms. Ferman has nothing to disclose.
Vijay K. Ramanan, MD, PhD (Mayo Clinic) The institution of Dr. Ramanan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Daridorexant trial for AD prevention (funded by Weston Family Foundation). The institution of Dr. Ramanan has received research support from the National Institutes of Health. The institution of Dr. Ramanan has received research support from the Mangurian Foundation for Lewy Body Disease Research. The institution of Dr. Ramanan has received research support from as part of clinical trials sponsored by the Alzheimer's Association, Eisai, the Alzheimer's Treatment and Research Institute at USC, and Transposon Therapeutics, Inc.. The institution of Dr. Ramanan has received research support from Medscape. The institution of Dr. Ramanan has received research support from Expert Perspectives in Medicine. The institution of Dr. Ramanan has received research support from Roche/ADLM. The institution of Dr. Ramanan has received research support from American College of Radiology. Dr. Ramanan has received personal compensation in the range of $500-$4,999 for serving as a Conference Speaker/Organizer (Honoraria) with AANI. Dr. Ramanan has received personal compensation in the range of $500-$4,999 for serving as a Speaker/CME Content with Clinical Care Options.
Jonathan Graff-Radford, MD, FAAN Dr. Graff-Radford has received personal compensation for serving as an employee of Mayo Clinic. Dr. Graff-Radford has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NINDS/NIH. Dr. Graff-Radford has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. Dr. Graff-Radford has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Open evidence . The institution of Dr. Graff-Radford has received research support from NIH. The institution of Dr. Graff-Radford has received research support from Eisai. The institution of Dr. Graff-Radford has received research support from Cognition therapeutics. Dr. Graff-Radford has received personal compensation in the range of $5,000-$9,999 for serving as a Faculty Member with IMPACT AD .
David T. Jones, MD (Mayo Clinic) Dr. Jones has stock in Cephlodyne Neurotechnologies, Inc.. Dr. Jones has received intellectual property interests from a discovery or technology relating to health care.
Rodolfo Savica, MD, PhD, FAAN (Mayo Clinic) The institution of Dr. Savica has received research support from ACADIA Pharmaceuticals, Inc.
Ross Reichard Ross Reichard has nothing to disclose.
Joseph E. Parisi, MD (Mayo Clinic) Dr. Parisi has nothing to disclose.
Aivi Nguyen (Mayo Clinic) Aivi Nguyen has nothing to disclose.
Dennis W. Dickson, MD (Mayo Clinic) Dr. Dickson has nothing to disclose.
Melissa Murray, PhD (Mayo Clinic) Dr. Murray has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Avid Radiopharmaceuticals. The institution of Dr. Murray has received research support from National Institute on Aging. The institution of Dr. Murray has received research support from Alzheimer's Association. The institution of Dr. Murray has received research support from Chan Zuckerberg Initiative.
Gregory S. Day, MD, MSc, FAAN (Mayo Clinic) Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys Therapeutics. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for DynaMed (EBSCO Health). Dr. Day has or had stock in ANI Pharmaceuticals. The institution of Dr. Day has received research support from National Institutes of Health / NIA. The institution of Dr. Day has received research support from National Institutes of Health / NINDS. The institution of Dr. Day has received research support from Amgen Pharmaceuticals. The institution of Dr. Day has received research support from AVID Radiopharmaceuticals. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Presenter at Annual Meeting (CME) with 好色先生. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Content Development (CME) with PeerView, Inc. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving as a Content Development (CME) with Continuing 好色先生, Inc. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving as a Content Development (CME) with Ionis Pharmaceuticals. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a 好色先生al Case Development + Presentation (video) with PeerDirect (P\S\L Group). Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Content Development / Presentation (non-CME) with MJH Life Sciences (NeurologyLive). Dr. Day has a non-compensated relationship as a Clinical Director with Anti-NMDA Receptor Encephalitis Foundation that is relevant to AAN interests or activities.
Neill R. Graff-Radford, MD, FAAN (Mayo Clinic Jacksonville) The institution of Dr. Graff-Radford has received research support from Biogen. The institution of Dr. Graff-Radford has received research support from Lilly. The institution of Dr. Graff-Radford has received research support from Eisai. The institution of Dr. Graff-Radford has received research support from Biogen. Dr. Graff-Radford has received publishing royalties from a publication relating to health care.
Erik K. St. Louis, MD (Mayo Clinic) The institution of Dr. St. Louis has received research support from NIH. Dr. St. Louis has received publishing royalties from a publication relating to health care. Dr. St. Louis has received publishing royalties from a publication relating to health care.
Manoj K. Jain, MD, MBBS Dr. Jain has nothing to disclose.
Kejal Kantarci, MD (Mayo Clinic) The institution of Dr. Kantarci has received research support from Eli Lilly. The institution of Dr. Kantarci has received research support from NIH. The institution of Dr. Kantarci has received research support from ADDF. The institution of Dr. Kantarci has received research support from Eisai. The institution of Dr. Kantarci has received research support from BioArctic.
Val J. Lowe, MD (Mayo Clinic) Dr. Lowe has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AVID Radiopharmaceutical. Dr. Lowe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Inc. The institution of Dr. Lowe has received research support from AVID Radiopharmaceuticals.
Bradley F. Boeve, MD, FAAN (Mayo Clinic) Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care.